 Glaukos Corporation NYSE: GKOS the Company or Glaukos, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it intends to offer, subject to market and other conditions, 200 million aggregate principal amount of Convertible Senior Notes due 2027 the notes in a private offering. The notes will be offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended the Securities Act. Glaukos expects to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional 30 million aggregate principal amount of the notes. 